Palatin Technologies (NYSE:PTN) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Palatin Technologies (NYSE:PTN) in a research note issued on Saturday. The firm set a “sell” rating on the stock.

Palatin Technologies Price Performance

Shares of PTN opened at $0.21 on Friday. Palatin Technologies has a 52 week low of $0.16 and a 52 week high of $2.48. The stock has a market cap of $5.38 million, a PE ratio of -0.13 and a beta of 0.89.

Palatin Technologies Company Profile

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.